Fellow's quick read · Infectious Diseases
Febrile neutropenia
ECIL-10 2024 (anchor) + NCCN v1.2026 + our institution CPG 2020 · reviewed 2026-06-21
Personal study digest for a new ID fellow. Recommendations are drawn from the ECIL-10 2024 empirical-therapy guideline (haematology/HCT focus), NCCN Prevention & Treatment of Cancer-Related Infections v1.2026 (risk stratification + US empiric choices), and the local our institution CPG (doses). The “What’s changed since 2024” section is reviewer synthesis of newer evidence, each claim cited. Not a substitute for the full guidelines.
In one line
Neutropenic fever is an emergency: ANC <500 (or expected to fall <500 within 48 h) plus a single temp ≥38.3 °C (101 °F) or ≥38.0 °C (100.4 °F) sustained ≥1 h. Draw cultures and give an antipseudomonal β-lactam within ~60 min, then risk-stratify (MASCC/CISNE) — that decides inpatient IV vs outpatient oral, and modern data let you stop on clinical criteria, not on the neutrophil count.◆When to suspect / diagnose
- Definition: ANC <500 cells/mm³ (or expected to fall below within 48 h) + temp ≥38.3 °C once or ≥38.0 °C sustained ≥1 h. Avoid rectal temperatures when neutropenic (mucosal translocation).
- ≥2 blood-culture sets before antibiotics — one set from each central-line lumen + one peripheral; label by source. Do not delay antibiotics for cultures. Candida grows in routine bottles (no fungal isolator needed).
- Review prior microbiology for resistant colonization/infection (MRSA, VRE, ESBL, CRE, DTR Pseudomonas) — this single fact drives the escalation-vs-de-escalation choice below.
- Most episodes have no documented source; neutropenia blunts localizing signs, so a normal exam does not reassure.
◆Risk stratification — the fellow drives this
- Low risk → oral/outpatient candidate: MASCC ≥21 or CISNE <3, outpatient at fever onset, anticipated brief neutropenia (≤100 cells/µL for <7 d), ECOG 0–1, no hepatic/renal dysfunction, no unstable comorbidity.
- High risk → admit for IV: MASCC <21 or CISNE ≥3, inpatient at onset, allogeneic HCT, anticipated profound neutropenia ≥7 d, hemodynamic instability, pneumonia/complex infection, hepatic insufficiency (transaminases >5× ULN), CrCl <30, or mucositis grade 3–4.
- MASCC (max 26) weights: no/mild symptoms 5, no hypotension 5, no COPD 4, solid tumor or heme malignancy w/o prior fungal infection 4, no dehydration 3, outpatient 3, age <60 = 2.
◆Empiric therapy
| Scenario | Drug / dose / route | Notes |
|---|---|---|
| Low-risk, oral (outpatient) | Ciprofloxacin + amoxicillin-clavulanate (category 1) | Only if tolerating PO, no N/V, and not on prior fluoroquinolone prophylaxis; levo/moxi are alternatives |
| High-risk, stable, uncomplicated (escalation) | Cefepime 2 g IV q8h or piperacillin-tazobactam 4.5 g IV q6h | Antipseudomonal β-lactam MONOTHERAPY; ceftazidime now NCCN category 2B (weak GP cover, breakthroughs) |
| Abdominal source | Piperacillin-tazobactam 4.5 g IV q6h | Anaerobic + Pseudomonas cover; send C. difficile PCR if diarrhea |
| Sepsis/shock, known resistant colonization, or high-resistance center (de-escalation) | Meropenem 1 g IV q8h ± aminoglycoside | ECIL-10: carbapenem in the critically ill upgraded to AIIu; de-escalate by 72–96 h on culture/clinical data |
| Add a glycopeptide ONLY if… | Vancomycin (AUC-guided) — daptomycin/linezolid if VRE history | Not routine (ECIL-10 DIIru). Triggers: suspected CRBSI, MRSA colonization, radiographic PNA, SSTI, severe mucositis, hemodynamic instability |
| Severe β-lactam allergy | Aztreonam 2 g IV q8h + vancomycin | Add gentamicin if septic; metronidazole if abdominal source |
| Known carbapenem-R GN colonization (empiric novel β-lactam) | Ceftazidime-avibactam (KPC, OXA-48); cefta-avi + aztreonam (MBL); high-dose ceftolozane-tazobactam or cefta-avi (DTR Pseudomonas) | New in ECIL-10. Add streptococcal cover if using a poor-GP agent + severe mucositis (CIII) |
◆Duration & stopping
- Stop empiric antibiotics in FUO after ≥72 h of treatment if the patient is hemodynamically stable since presentation and afebrile ≥48 h — IRRESPECTIVE of the neutrophil count or expected duration of neutropenia (ECIL-10; high-risk BI, intermediate-risk AI). A stable patient with persistent fever is not a reason to escalate — continue the work-up.
- Gram-negative bacteremia: ≥7 days (ECIL-10 — with ANC recovery AIIu, without recovery BIIu), given source control and clinical resolution.
- Empiric antifungals for persistent/new fever after 4–7 d of broad-spectrum antibiotics with no source: image first (CT chest + sinus) → micafungin if chest CT clear, or voriconazole/liposomal amphotericin B if infiltrates or already on mold-active prophylaxis.
- Local our institution option: de-escalate to oral prophylaxis before count recovery if ≥5 d of therapy, afebrile 48 h, stable, and no identified source.
◆Key decisions a fellow owns
- Escalation vs de-escalation — driven by stability (sepsis/shock), resistance history/colonization, and local epidemiology, not reflex.
- Resist two habits: adding vancomycin without an indication, and escalating for isolated persistent fever in a stable patient.
- Source control — remove/replace infected catheters, drain collections.
- When to stop — by clinical criteria (above), not by waiting for ANC ≥500.
- ID consult for S. aureus bacteremia, MDR pathogens, invasive mold, or instability/persistent fever despite broad antibacterial + antifungal cover.
What’s changed since 2024
Reviewer synthesis of newer evidence — not the guideline. Each claim cited; flags where the US IDSA document lags current practice.
- ECIL-10 is now a peer-reviewed manuscript — the Sept-2024 slide set was published in Lancet Infectious Diseases (online Nov 25, 2025). It is the current go-to over the 15-year-old IDSA inpatient guideline (Freifeld 2010) and the 2018 ASCO/IDSA outpatient guideline. doi:10.1016/S1473-3099(25)00619-X
- De-escalation trigger redefined — ECIL-10 replaced ECIL-4’s vague “complicated presentation” with SEPSIS/septic shock, and upgraded the carbapenem indication in the critically ill to AIIu. ECIL-10 2024
- Stop on clinical criteria, not on the ANC — the practice-changing shift. The How Long RCT (157 high-risk haematology FUO episodes): clinically-driven discontinuation gave more antibiotic-free days (16.1 vs 13.6, p=0.026) with no excess mortality. ECIL-10 now grades this AI/BI. Aguilar-Guisado, Lancet Haematol 2017;4:e573–583 · PMID 29153975 · doi
- Gram-negative bacteremia ≥7 days is now explicitly endorsed (ECIL-10) — neutropenia per se no longer mandates treating until count recovery.
- Novel anti-GN β-lactams entered empiric use for patients colonized/previously infected with carbapenem-resistant GN: ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-relebactam, cefiderocol. Sulbactam-durlobactam (Xacduro, FDA May 23 2023) + high-dose imipenem is first-line for CRAB (AIIt, as combination therapy). Aztreonam-avibactam (Emblaveo) gained US FDA approval Feb 7 2025 — ECIL-10 had listed it as provisional/not-yet-approved for MBL producers. Recency-sensitive — confirm formulary availability. FDA approvals 2023/2025
- A dedicated FN RCT of a new agent — imipenem-relebactam vs standard of care (mostly cefepime, n=100): better favourable response at end-of-IV (90% vs 74%, p=0.042) but similar at test-of-cure; small/exploratory, not practice-changing. J Antimicrob Chemother 2024 · PMID 39092963 · doi
- Non-culture diagnostics (multiplex PCR, T2MR, mNGS, MALDI-TOF) speed organism/resistance identification but ECIL-10 found no proven survival benefit in FN — keep drawing blood cultures; use rapid tests alongside, not instead.
◆Anki cards minted this run
- How Long / ECIL-10 — stop empiric antibiotics by clinical criteria irrespective of ANC.
- ECIL-10 escalation → de-escalation trigger (sepsis/septic shock → carbapenem).
- Gram-negative bacteremia duration in neutropenia (≥7 days).
- MASCC ≥21 = low risk → oral outpatient therapy.
- Held (cap 4): CRAB = sulbactam-durlobactam + HD imipenem combination; empiric vancomycin indications and antifungal timing already in deck.
Sources: ECIL-10 empirical/targeted therapy in FN (Lancet Infect Dis 2025, doi:10.1016/S1473-3099(25)00619-X; final slide set Sept 2024); How Long study (Lancet Haematol 2017;4:e573–583; PMID 29153975; doi:10.1016/S2352-3026(17)30211-9); NCCN Prevention & Treatment of Cancer-Related Infections v1.2026 (MASCC/CISNE, empiric choices); ASCO/IDSA Outpatient FN 2018 (doi:10.1200/JCO.2017.77.6211); IDSA neutropenic-fever guideline (Freifeld, Clin Infect Dis 2011;52:e56–e93); imipenem-relebactam FN RCT (J Antimicrob Chemother 2024; PMID 39092963; doi:10.1093/jac/dkae254); sulbactam-durlobactam FDA approval (May 23 2023); aztreonam-avibactam FDA approval (Feb 7 2025); our institution Febrile Neutropenia CPG (2020). PubMed used for How Long and the imipenem-relebactam RCT.